 HEIDELBERG, Germany, Feb. 08, 2022 GLOBE NEWSWIRE -- Affimed N.V. Nasdaq: AFMD, a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that management will present and host one-on-one meetings at the following investor conferences during the month of February 2022. 